Cargando…
Discrepancies between European countries and USA and Canada in the availability of triptans and in their licensed clinical properties
Triptans are presently a milestone in the treatment of migraine patients. Because of their effectiveness and safety, they have radically improved migraine treatment but their use has meant a substantial increase in spending for medicines. We compared available pharmaceutical forms, pack sizes, indic...
Autores principales: | Stirparo, Giuseppe, Palazzo, Fabio, De Filippis, Sergio, Martelletti, Paolo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag Italia
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3611693/ http://dx.doi.org/10.1007/s101940300019 |
Ejemplares similares
-
Price differentials of oral triptans in eight European Union countries
por: Folino-Gallo, Pietro, et al.
Publicado: (2003) -
Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine
por: Gentile, Giovanna, et al.
Publicado: (2010) -
Frequencies of genetic polymorphisms related to triptans metabolism in chronic migraine
por: Gentile, Giovanna, et al.
Publicado: (2010) -
Number of pathologists in Germany: comparison with European countries, USA, and Canada
por: Märkl, Bruno, et al.
Publicado: (2020) -
European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure
por: Sacco, Simona, et al.
Publicado: (2022)